Lumida
/PGEN
⌘K
Precigen Inc

Precigen Inc

PGEN
$4.95USD↑+0.00%+0.00 today

MARKET CAP

1.8B

P/E (TTM)

—

FWD P/E

104.0x

DAY RANGE

$5 – $5

52W RANGE

$1
$6

AI Summary

Stalk
TrimMedium

PGEN remains in a longer-term uptrend, but the recent clear support failure and short-EMA breakdown have shifted the medium-term bias bearish. Short-term momentum is weak with price below declining 9/21 EMAs and near the 50DMA, making immediate selling unfavorable. Execution will seek rallies into the 9/21 EMA and 50DMA resistance zone for trimming positions. Key risks include a sharp bounce trapping sellers and a deeper breakdown accelerating into a Stage 3 distribution.

  • ↑FDA orphan exclusivity secures seven-year protection for PAPZIMEOS.
  • ↑Q1 2026 revenue expected >$18 M after FY 2025 sales rose to $9.7 M (+149% YoY).
  • ↓Negative earnings yield and profitability factors signal long-term viability risks.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Precigen Inc. (NASDAQ:PGEN) specializes in developing innovative gene therapies and immunotherapies, particularly targeting recurrent respiratory papillomatosis (RRP), an HPV-related disease. With their lead product, PAPZIMEOS, approved by the FDA and enjoying orphan drug exclusivity through a seven-year market protection period, Precigen is strategically positioned within the expanding oncology sector. The company's focus on groundbreaking treatments with favorable clinical outcomes places it at the forefront of addressing unmet medical needs, particularly in rare diseases.

Bull says

  • ↑FDA orphan exclusivity secures seven-year protection for PAPZIMEOS.
  • ↑Q1 2026 revenue expected >$18 M after FY 2025 sales rose to $9.7 M (+149% YoY).
  • ↑Patient support hub now covers ~215 M lives, boosting payer access.
  • ↑Clinical data show 86% of patients cut surgical burden post-treatment.
  • ↑Analysts lifted fair value from $8.50 to $12.45, citing robust adoption.
  • ↑Strong momentum factors and growing 13F ownership indicate investor interest.

Bear says

  • ↓Negative earnings yield and profitability factors signal long-term viability risks.
  • ↓Net loss of $429.6 M ($1.37/share) in FY 2025 underscores cash burn concerns.
  • ↓Burn of $68.5 M in 2023 leaves $100.4 M cash—break-even not until late 2026.
  • ↓High volatility factor suggests wide price swings, undermining investor confidence.
  • ↓Payer reimbursement hurdles could limit patient uptake and revenue growth.
  • ↓Competitive pressure from Amgen, Novavax and BMS may erode market share.

Investment themes with PGEN

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-01-2026bullish

Transcript signals

Bull points

  • As of today, that number is well over 300, indicative of the pent-up demand for the new standard of care for adults with RRP.
  • Payer coverage continues to expand. In early January, we had approximately 170 million lives covered, which has now increased to approximately 215 million, including nearly all major payers across commercial, Medicare, and Medicaid.
  • we now have approximately 90% of insured lives covered in the U.S., which is phenomenal progress for a rare disease drug like pap smear.

Bear points

  • Our net loss attributable to common shareholders was $429.6 million, or $1.37 per share, but the year ended December 31, 2025.
  • Our net loss attributable to common shareholders was $429.6 million, or $1.37 per share, but the year ended December 31, 2025.
Read full transcript analysis ›